Journal Home > Volume 2 , Issue 1
Cancer Innovation 2023, 2(1): 25-35 https://doi.org/10.1002/cai2.56
Review | Open Access | Issue | Published: 01 March 2023

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Show Author's Information Yan Huang,  Li Zhang( )
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China
Keywords:
targeted therapy, ALK, driver gene-positive lung cancer, EGFR, rare mutations
Cite this article:
Huang Y, Zhang L. Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022. Cancer Innovation, 2023, 2(1): 25-35. https://doi.org/10.1002/cai2.56
Download citation
EndNote(RIS)
BibTeX

328

Views

17

Downloads

Citations

3

Crossref

N/A

WoS

2

Scopus

N/A

CSCD

Abstract Full text About this article

With the rapid development of lung cancer molecular detection and precision therapy, targeted therapy has covered the entire process of diagnosis and treatment of nonsmall cell lung cancer patients. Overall mortality from lung cancer has decreased significantly over the past 20 years, especially since the introduction of targeted drugs in 2013. In 2022, targeted therapy for lung cancer has developed rapidly. The optimization of treatment modes and the exploration of new target drugs such as antibody-drug conjugates will broaden the selection range of nonsmall cell lung cancer patients with positive driver genes. This article reviews the latest advances in targeted therapy for driver gene-positive lung cancer in 2022.


menu
Abstract
Full text
Outline
About this article

Annual progress of clinical research on targeted therapy for nonsmall cell lung cancer in 2022

Show Author's information Yan Huang, Li Zhang( )
State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China

Abstract

With the rapid development of lung cancer molecular detection and precision therapy, targeted therapy has covered the entire process of diagnosis and treatment of nonsmall cell lung cancer patients. Overall mortality from lung cancer has decreased significantly over the past 20 years, especially since the introduction of targeted drugs in 2013. In 2022, targeted therapy for lung cancer has developed rapidly. The optimization of treatment modes and the exploration of new target drugs such as antibody-drug conjugates will broaden the selection range of nonsmall cell lung cancer patients with positive driver genes. This article reviews the latest advances in targeted therapy for driver gene-positive lung cancer in 2022.

Keywords: targeted therapy, ALK, driver gene-positive lung cancer, EGFR, rare mutations

References(55)

1

Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640–49. https://doi.org/10.1056/NEJMoa1916623
DOI Google Scholar
2

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492
DOI Google Scholar
3

Fois SS, Paliogiannis P, Zinellu A, Fois AG, Cossu A, Palmieri G. Molecular epidemiology of the main druggable genetic alterations in non-small cell lung cancer. Int J Mol Sci. 2021;22(2):612. https://doi.org/10.3390/ijms22020612
DOI Google Scholar
4

Chen G, Wang X, Liu Y, Wu L, Hao Y, Liu C, et al. Central nervous system efficacy of furmonertinib versus gefitinib in patients with non–small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study. J Clin Oncol. 2022;40:9101. https://doi.org/10.1200/JCO.2022.40.16_suppl.9101
DOI Google Scholar
5

Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, et al. AENEAS: a randomized phase iii trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon–small-cell lung cancer with EGFR Exon 19 Deletion or L858R Mutations. J Clin oncol. 2022;40(27):3162–71. https://doi.org/10.1200/JCO.21.02641
DOI Google Scholar
6

Nobuhisa I, Takashi N, Toshiyuki K, Shoichi K, Koji I, Toshihide Y, et al. Treatment of patients with EGFR-mutated advanced non-squamous NSCLC: Primary analysis of the multicenter, randomized, phase Ⅱ study—AfaBev-CS study. ASCO Abstract. 2022:9112.
DOI Google Scholar
7

Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, et al. Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study. J Thorac Oncol. 2022;17:1098–1108. https://doi.org/10.1016/j.jtho.2022.05.006
DOI Google Scholar
8

Atsushi N, Ryota S, Ryo K, Koichi A, Ryo M, Makoto M, et al. A phase Ⅱ study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: the OPAL study (NEJ032C/LOGIK1801). ASCO Abstract. 2022;40:9097.
DOI Google Scholar
9

Cho BC, Felip E, Hayashi H, Thomas M, Lu S, Besse B, et al. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer. Future Oncol. 2022;18(6):639–47. https://doi.org/10.2217/fon-2021-0923
DOI Google Scholar
10

Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor–resistant, EGFR-mutated non–small cell lung cancer. Cancer Discov. 2022;12(1):74–89. https://doi.org/10.1158/2159-8290.CD-21-0715
DOI Google Scholar
11

Ahn M-J, De Marinis F, Bonanno L, Cho BC, Kim TM, Cheng S, et al. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib + osimertinib in EGFRm NSCLC Post-osimertinib. WCLC EP08.02-140. 2022;17:S469–70.
DOI Google Scholar
12

Jonathan WG, Hidehito H, Byoung CC, Pascale T, Martin D, David H, et al. Phase 1/1b study of telisotuzumab vedotin (Teliso-V) plus osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer. J Clin Oncol. 2022;40(16):S9013.
DOI Google Scholar
13

Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, et al. Sintilimab with or without IB1305 plus chemotherapy in patients with EGFR mutated non-squamous non-small-cell lung cancer EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase(TKIs) therapy: second interim analysis of phase 3 ORIENT-31 study. ESMO LBA58. 2022;23:1167–79.
DOI Google Scholar
14

Yang JC-H, Wang M, Mitchell P, Fang J, Nian W, Chiu C, et al. EP08.02-029 sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations: effect of prior treatment. J Thorac Oncol. 2022;17:S410–11. https://doi.org/10.1016/j.jtho.2022.07.711
DOI Google Scholar
15

Zwierenga F, van Veggel B, Hendriks LEL, Hiltermann TJN, Hiddinga BI, Hijmering Kappelle LBM, et al. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial. Lung Cancer. 2022;170:133–40. https://doi.org/10.1016/j.lungcan.2022.06.012
DOI Google Scholar
16

Pizzutilo EG, Cerea G, Oresti S, Agostara AG, Signorelli D, Stabile S, et al. 996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO). Ann Oncol. 2022;33:S1009. https://doi.org/10.1016/j.annonc.2022.07.1122
DOI Google Scholar
17

Qing Z, Kim HR, Soo RA, Chiu CH, Hayashi H, Kim S, et al. Updated analyses from the CROWN study of first-line lorlatinib vs crizotinib in Asian patients with ALK-positive non-small cell lung cancer (NSCLC). ESMO 992P. 2022;33:S1007. https://doi.org/10.1016/j.annonc.2022.07.1119
DOI Google Scholar
18

Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, et al. Final overall survival analysis from the phase Ⅲ J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer. ESMO Open. 2022;7(4):100527. https://doi.org/10.1016/j.esmoop.2022.100527
DOI Google Scholar
19

Lu S, Zhou Q, Liu X, Du Y, Fan Y, Cheng Y, et al. Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People's Republic of China. J Thorac Oncol. 2022;17(6):816–26. https://doi.org/10.1016/j.jtho.2022.02.014
DOI Google Scholar
20

Lu S, Fang J, Li X, Cao J, Zhou Q, Guo Z, et al. Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC. Ann Oncol. 2022;33:S27–70.
DOI Google Scholar
21

Thomas M, Garassino M, Felip E, Sakai H, Le X, Veillon R, et al. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: primary Analysis of the Confirmatory VISION Cohort C. J Thorac Oncol. 2022;17:S9–10. https://doi.org/10.1016/j.jtho.2022.07.024
DOI Google Scholar
22

Lu S, Yu Y, Zhou J, Goto K, Li X, Sakakibara-Konishi J, et al. Phase Ⅱ study of SCC244 in NSCLC patients harboring MET exon 14 skipping (METex14) mutations (GLORY study). Cancer Res. 2022;82(12_Suppl):CT034. https://doi.org/10.1158/1538-7445.AM2022-CT034.
DOI Google Scholar
23

Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, et al. Trastuzumab deruxtecan in HER2 mutant non–small-Cell Lung Cancer. N Engl J Med. 2022;386(3):241–51. https://doi.org/10.1056/NEJMoa2112431
DOI Google Scholar
24

Fan Y, Jianying Z, Yuanyuan Z, Yan Y, Nong Y, Juan L, et al. Safety and efficacy of dabrafenib plus trametinib in Chinese patients with BRAF V600E-mutation positive metastatic NSCLC. J Thorac Oncol. 2022;17(9):S423. https://doi.org/10.1016/j.jtho.2022.07.734
DOI Google Scholar
25

Besse B, Griesinger F, Curigliano G, Thomas M, Subbiah V, Baik CS, et al. 1170P Updated efficacy and safety data from the phase Ⅰ/Ⅱ ARROW study of pralsetinib in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). Ann Oncol. 2022;33:S1083–84. https://doi.org/10.1016/j.annonc.2022.07.1293
DOI Google Scholar
26

Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, et al. Durability of efficacy and safety with selpercatinib in patients with RET fusion+ non-small-cell lung cancer: LIBRETTO-001. J Clin Oncol. 2022;33:S43.
DOI Google Scholar
27

Lu S, Cheng Y, Huang D, Sun Y, Wu L, Zhou C, et al. Efficacy and safety of selpercatinib in Chinese patients with advancedRETfusion-positive non-small-cell lung cancer: a phase Ⅱ clinical trial (LIBRETTO-321). Ther Adv Med Oncol. 2022;14:17588359221105020. https://doi.org/10.1177/17588359221105020
DOI Google Scholar
28

Johnson ML, de Langen AJ, Waterhouse DM, Mazieres J, Dingemans AMC, Mountzios G, et al. LBA10 Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase Ⅲ study. Ann Oncol. 2022;33:S1417–18. https://doi.org/10.1016/j.annonc.2022.08.051
DOI Google Scholar
29

Spira AI, Riely GJ, Gadgeel SM, Heist RS, Ou SHI, Pacheco JM, et al. KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation. J Clin Oncol. 2022;40:9002. https://doi.org/10.1200/JCO.2022.40.16_suppl.9002
DOI Google Scholar
30

Michels SYF, Franklin J, Massuti B, Sebastian M, Felip E, Grohé C, et al. Crizotinib in ROS1-rearranged lung cancer (EUCROSS): updated overall survival. J Clin Oncol. 2022;40:S9078. https://doi.org/10.1200/JCO.2022.40.16_suppl.9078
DOI Google Scholar
31

Fan Y, Drilon A, Chiu C, Bowles D, Loong H, Siena S, et al. Entrectinib in patients with ROS1 fusion-positive (ROS1-fp) NSCLC: updated efficacy and safety analysis. WCLC. 2022;17(9):S89–S90. https://doi.org/10.1016/j.jtho.2022.07.150
DOI Google Scholar
32

Lu S, Pan H, Wu L, Yao Y, He J, Wang Y, et al. The phase Ⅱ study of unecritinib (TQ-B3101) monotherapy in the first line treatment in patients with ROS1 positive non-small cell lung cancer (NCT03972189). ELCC. 2022;33:S31.
DOI Google Scholar
33

Moreno V, Lin JJ, Tan DSW, Kummar S, Dai M-S, Lassen UN, et al. Extended follow-up of efficacy and safety of larotrectinib in patients with TRK fusion lung cancer. WCLC. 2022;17(9):S473–S474. https://doi.org/10.1016/j.jtho.2022.07.831
DOI Google Scholar
34

Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, et al. Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res. 2022;28(7):1302–12. https://doi.org/10.1158/1078-0432.CCR-21-3597
DOI Google Scholar
35

Lu L, Chiu C-H, Yu Y, Loong HHF, Lin CC, Hu X, et al. Entrectinib in Chinese patients with metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours. ELCC. 2022;33:S83–S84.
DOI Google Scholar
36

Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020;61:167–79. https://doi.org/10.1016/j.semcancer.2019.09.015
DOI Google Scholar
37

Lyu C, Fang W, Ma H, Wang J, Jiao W, Wang R, et al. Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage Ⅱ-ⅢB lung adenocarcinoma (NEOS): updated results. ELCC. 2022;33:S71–S72. https://doi.org/10.1016/j.annonc.2022.02.091
DOI Google Scholar
38

Tsuboi M, Wu Y-L, Grohe C, John T, Majems M, Wang J, et al. Osimertinib as adjuvant therapy in patients with resected EGFR Mutated stage IB-ⅢA NSCLC: updated results from ADAURA. ESMO LBA47. 2022;33(suppl_7):S808–S869.
DOI Google Scholar
39

Yue D, Xu S, Wang Q, Li X, Shen Y, Zhao H, et al. Updated overall survival and exploratory analysis from randomized, phase ii evan study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in Stage ⅢA epidermal growth factor receptor+ non-small-cell lung cancer. J Clin Oncol. 2022;40(34):3912–17. https://doi.org/10.1200/JCO.22.00428
DOI Google Scholar
40

Zhang JT, Liu SY, Gao W, Liu SYM, Yan HH, Ji L, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer. Cancer Discov. 2022;12(7):1690–1701. https://doi.org/10.1158/2159-8290.CD-21-1486
DOI Google Scholar
41

Shum E, Elamin YY, Piotrowska Z, Spigel DR, Reckamp KL, Rotow JK, et al. A phase 1/2 study of BLU-945 in patients with common activating EGFRmutant non–small cell lung cancer (NSCLC): SYMPHONY trial in progress. J Clin Oncol. 2022;40(16):TPS9156.
DOI Google Scholar
42

Garon EB, Johnson ML, Lisberg AE, Spira A, Yamamoto N, Heist RS, et al. LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase Ⅰ TROPION-PanTumor01 study. Ann Onco. 2021;32:S1326–27. https://doi.org/10.1016/j.annonc.2021.08.2128
DOI Google Scholar
43

Fang W, Huang Y, Hong S, Zhang Z, Wang M, Gan J, et al. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer. BMC Cancer. 2019;19(1):595. https://doi.org/10.1186/s12885-019-5820-0
DOI Google Scholar
44

Passaro A, Mok T, Peters S, Popat S, Ahn MJ, de Marinis F. Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations. J Thorac Oncol. 2021;16(5):764–73. https://doi.org/10.1016/j.jtho.2020.12.002
DOI Google Scholar
45

Yang JCH, Schuler M, Popat S, Miura S, Heeke S, Park K, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol. 2020;15(5):803–15. https://doi.org/10.1016/j.jtho.2019.12.126.
DOI Google Scholar
46
NCCN Guidelines Version 3.2022 Non-Small Cell Lung Cancer.
47

Liu S, Huang T, Liu M, He W, Zhao Y, Yang L, et al. The genomic characteristics of ALK fusion positive tumors in chinese NSCLC patients. Front Oncol. 2020;10:726. https://doi.org/10.3389/fonc.2020.00726
DOI Google Scholar
48

Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Onco. 2020;31(8):1056–64. https://doi.org/10.1016/j.annonc.2020.04.478
DOI Google Scholar
49

Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020;17(9):569–87. https://doi.org/10.1038/s41571-020-0377-z
DOI Google Scholar
50

Goto K, Kim S-W, Kubo T, Goto Y, Ahn M-J, Planchard D, et al. Trastuzumab deruxtecan in patients with HER2 mutant metastatic non–small-cell lung cancer: interim results from the phase 2 DESTINY-lung02 trial. ESMO. 2022;33(suppl_7):S808–S869. https://doi.org/10.1016/j.annonc.2022.08.057.
DOI Google Scholar
51

Bustamante JG, Otterson GA. Agents to treat BRAF-mutant lung cancer. Drugs Context. 2019;8:212566. https://doi.org/10.7573/dic.212566
DOI Google Scholar
52

Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, et al. RET fusions in solid tumors. Cancer Treat Rev. 2019;81:101911. https://doi.org/10.1016/j.ctrv.2019.101911
DOI Google Scholar
53

Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019;19:495–509. https://doi.org/10.1038/s41568-019-0179-8
DOI Google Scholar
54
2022WCLC.OA03.04/OA03.07.
55

Liu F, Wei Y, Zhang H, Jiang J, Zhang P, Chu Q. NTRK fusion in non-small cell lung cancer: diagnosis, therapy, and TRK inhibitor resistance. Front Oncol. 2022;12:864666. https://doi.org/10.3389/fonc.2022.864666
DOI Google Scholar
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 04 December 2022
Accepted: 31 January 2023
Published: 01 March 2023
Issue date: February 2023

Copyright

© 2023 The Authors. Cancer Innovation published by John Wiley & Sons Ltd. on behalf of Tsinghua University Press.

Acknowledgements

ACKNOWLEDGMENTS

None.

Rights and permissions

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Return